Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

• Astrid van Tubergen,
• Gertjan Wolbink,
• Alejandro Balsa,
• Victoria Navarro-Compán,
• Denis Mulleman,
• John Isaac,
• Meghna Jani,
• Borja Hernandez-Breijo,
• Johanna Elin Gehin,
• Charlotte Krieckaert,
• Guillaume le Mélédo

Affiliations

Astrid van Tubergen

Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands

Gertjan Wolbink

Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands

Alejandro Balsa

Rheumatology, Hospital Universitario La Paz, Madrid, Spain

Victoria Navarro-Compán

Rheumatology, La Paz University Hospital, Madrid, Spain

Denis Mulleman

Department of Rheumatology, CHRU de Tours, Tours, France

John Isaac

Department of Critical Care and Anaesthesia, Queen Elizabeth Hospital Birmingham, Birmingham, UK

Meghna Jani

6Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Borja Hernandez-Breijo

1Immuno-Rheumatology Research Group, IdiPaz, La Paz University Hospital

Johanna Elin Gehin

Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway

Charlotte Krieckaert

Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands

Guillaume le Mélédo

Department of Rheumatology, University of Tours, Tours, France